<code id='2480C23507'></code><style id='2480C23507'></style>
    • <acronym id='2480C23507'></acronym>
      <center id='2480C23507'><center id='2480C23507'><tfoot id='2480C23507'></tfoot></center><abbr id='2480C23507'><dir id='2480C23507'><tfoot id='2480C23507'></tfoot><noframes id='2480C23507'>

    • <optgroup id='2480C23507'><strike id='2480C23507'><sup id='2480C23507'></sup></strike><code id='2480C23507'></code></optgroup>
        1. <b id='2480C23507'><label id='2480C23507'><select id='2480C23507'><dt id='2480C23507'><span id='2480C23507'></span></dt></select></label></b><u id='2480C23507'></u>
          <i id='2480C23507'><strike id='2480C23507'><tt id='2480C23507'><pre id='2480C23507'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:fashion    Page View:73
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In